XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 25.65

+2.7%

Jan 30 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Cacaito who wrote (11285)	8/17/1999 2:10:00 AM
From: aknahow	Read Replies (4) of 17367

Given my prior post indicating that combined endpoints lower the power of a trial to demonstrate the efficacy of the single endpoints I am not sure release of the data would mean that much. Clearly the FDA needs more analysis of the data. But I would feel better seeing the mortality in both arms. One could then make a decision on how far from statistical significance BPI was. If the info. I have posted is correct it may be that even 12 or 13 deaths in the treatment arm vs 22 or 21 in the placebo do not provide statistical significance but it would IMO still be a very positive sign.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next